Clinical Trials Directory

Trials / Completed

CompletedNCT02012998

Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
751 (actual)
Sponsor
Sanofi Pasteur, a Sanofi Company · Industry
Sex
All
Age
10 Years – 12 Years
Healthy volunteers
Accepted

Summary

To evaluate the immune response to Hepatitis B virus in children who have been primed with HEXAVAC or INFANRIX HEXA 10 years ago.

Conditions

Interventions

TypeNameDescription
BIOLOGICALHBVAXPRO 5µg0.5mL intramuscular injection

Timeline

Start date
2014-01-01
Primary completion
2015-02-01
Completion
2015-02-01
First posted
2013-12-17
Last updated
2017-09-11

Locations

10 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT02012998. Inclusion in this directory is not an endorsement.